Bristol Myers Squibb Company is paying $14bn to rapidly ramp up its neuroscience portfolio through the acquisition of Karuna Therapeutics, Inc. and its M1/M4 receptor agonist KarXT (xanomeline-trospium), which is filed with the US Food and Drug Administration for the treatment of schizophrenia with a 26 September 2024 action date. The deal announced on 22 December gives BMS a product with blockbuster potential across multiple indications plus much-needed diversification of its portfolio.
BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy
Schizophrenia Drug Approval Expected In September
Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.
More from Deals
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
More from Business
• By
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.